Biomarkers in Cardiology: A Critical Appraisal of Historical Successes, Pitfalls, and Emerging Uses
In preventive cardiology, low-density lipoprotein cholesterol and blood pressure are validated surrogate endpoints, with multiple randomized trials demonstrating that their reduction improves cardiovascular morbidity and mortality. In contrast, raising high-density lipoprotein cholesterol (HDL-C) with niacin or cholesteryl ester transfer protein inhibitors failed to improve outcomes despite promising observational data and biological plausibility. In the Cardiac Arrhythmia Suppression Trial of class IC antiarrhythmics to suppress premature ventricular complexes, biomarker-targeted therapy increased mortality. Contemporary biomarkers, including lipoprotein(a), coronary artery calcium scoring, and high-sensitivity C-reactive protein, are increasingly used to refine risk and guide therapy. However, despite favorable guideline recommendations, randomized trials showing that biomarker-guided or biomarker-targeted treatment improves hard clinical endpoints are lacking. This review presents historical biomarker reversals in cardiology and critically appraises the evidence supporting emerging biomarkers. Our core argument is that practice recommendations for biomarker-guided therapy should await appropriately designed randomized trials adequately powered for cardiovascular events and mortality.
Authors
- Areez Shafqat (ORCID: https://orcid.org/0000-0002-1202-7214)
- Isra Khan
- Douglas S. Paauw
- Abdullah Shaik
- Mohammad Kazi
- Ahmed ElShaer
Institutions
- Mayo Clinic (US)
- Alfaisal University (SA)
- Henry Ford Health System (US)
- University of Washington (US)
- University of Michigan (US)
- Henry Ford Hospital (US)
- Michigan Medicine (US)
Publication Details
- Journal
- Cardiology in Review
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1097/crd.0000000000001546
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00